OLIO is an immunotherapy clinical trial which is examining whether the addition of olaparib to standard chemotherapy, with or without durvalumab, will improve outcomes for young, pre-menopausal women with high-risk, early breast cancer. Dr Stephen Luen is the Study Chair of the OLIO clinical trial, and we spoke to him about the aim of this research, how it might improve patient outcomes, and his hopes for the future of breast cancer research.
